NCT05791591 - Safety and Efficacy of Orally Administered NUV001 Nutraceutical Supplement in Sickle Cell Disease Patients | Biotech Hunter

Enrollment

168

Participants

Timeline

Start Date

April 15, 2023

Primary Completion Date

October 31, 2024

Study Completion Date

November 30, 2024

Conditions

Sickle Cell Disease

Interventions

DIETARY_SUPPLEMENT

NUV001 - IR

Daily supplementation with 1000 mg of NUV001 (in two administration orally) immediate release gel capsule formulation for 90 days in total

DIETARY_SUPPLEMENT

NUV001 - GR

Daily supplementation with 1000 mg of NUV001 (in two administration orally) gastro resistant gel capsule formulation for 90 days in total

DIETARY_SUPPLEMENT

Placebo

Placebo containing starch Powder (1000 mg, daily in two administration orally for 90 days)

Trial Locations (8)

Aman Hospital and Research Center, Vadodara

Kingsway Hospital, Nagpur

Sai Krupa Hospital & Research Centre, Ahmedabad

Thalassemia & Sickle Cell Society, Hyderabad

Index Medical College, Indore

NRSMC Hospital, Kolkata

Arihant Hospital, Nagpur

Shalinitai Meghe Hospital & Research Centre, Nagpur